HDAC1 and cancer: Interestingly, analysis of the Library of Integrated Network-Based Cellular Signatures (LINCS) drug screening database identified a notable overlap between transcriptomic changes induced by the HDAC1 inhibitor mocetinostat in various cancer cells and those seen in shRNF5-expressing MOLM-13 and HL-60 cells (Fig. 5d).